Access cutting-edge uveal melanoma treatment through this clinical trial at a research site in Palo Alto. Study-provided care at no cost to qualified participants.
Access uveal melanoma specialists in Palo Alto at no cost
This study follows strict safety protocols and ethical guidelines
All study-related uveal melanoma treatment provided free
The purpose of this study is to measure the clinical benefits of the combination of RP2 and nivolumab as compared with the combination of nivolumab and ipilimumab in patients with metastatic uveal melanoma who have not been treated with immune checkpoint inhibitor therapy.
Sponsor: Replimune Inc.
Check if you qualify for this uveal melanoma clinical trial in Palo Alto, CA
If you're searching for uveal melanoma treatment options in Palo Alto, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Palo Alto research site is actively enrolling participants for this clinical trial. You'll receive care from experienced uveal melanoma specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.